Monitoring of minimal residual disease in leukemia, advantages and pitfalls

References

• Szczepanski T., Orfao A., van der Velden V. H., San Miguel J. F., van Dongen J. J. Minimal residual disease in leukaemia patients. Lancet Oncol 2001; 2: 409–17
   PubMed Web of Science ®Google Scholar
• Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823–38
   PubMed Web of Science ®Google Scholar
• Cazzaniga G., Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 2005; 90: 382–90
   PubMed Web of Science ®Google Scholar
• San‐Miguel J. F., Vidriales M. B., Orfao A. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol 2002; 15: 105–18
   Google Scholar
• Campana D. Minimal residual disease studies in acute leukemia. Am J Clin Pathol 2004; 122(Suppl)S47–57
   PubMedGoogle Scholar
• Grimwade D., Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002; 16: 1959–73
   PubMed Web of Science ®Google Scholar
• Goldman J. Monitoring minimal residual disease in BCR‐ABL‐positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005; 12: 33–9
   PubMed Web of Science ®Google Scholar
• Armstrong S. A., Look A. T. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 6306–15
   PubMed Web of Science ®Google Scholar
• Frohling S., Scholl C., Gilliland D. G., Levine R. L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285–95
   PubMed Web of Science ®Google Scholar
• van Dongen J. J., Macintyre E. A., Gabert J. A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT‐PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED‐1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901–28
   PubMed Web of Science ®Google Scholar
• Pongers‐Willemse M. J., Seriu T., Stolz F., d'Aniello E., Gameiro P., Pisa P., et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukemia 1999; 13: 110–18
   PubMed Web of Science ®Google Scholar
• van Dongen J. J., Langerak A. W., Bruggemann M., Evans P. A., Hummel M., Lavender F. L., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T‐cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED‐2 Concerted Action BMH4‐CT98‐3936. Leukemia 2003; 17: 2257–317
   PubMed Web of Science ®Google Scholar
• Rosenfeld C., Cheever M. A., Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003; 17: 1301–12
   PubMed Web of Science ®Google Scholar
• Cilloni D., Gottardi E., Messa F., Fava M., Scaravaglio P., Bertini M., et al. Piedmont Study Group on Myleodysplastic Syndromes. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 1988–95
   PubMed Web of Science ®Google Scholar
• Cazzaniga G., d'Aniello E., Corral L., Biondi A. Results of minimal residual disease (MRD) evaluation and MRD‐based treatment stratification in childhood ALL. Best Pract Res Clin Haematol 2002; 15: 623–38
   Web of Science ®Google Scholar
• Gokbuget N., Kneba M., Raff T. Risk‐adapted treatment according to minimal residual disease in adult ALL. Best Pract Res Clin Haematol 2002; 15: 639–52
   PubMed Web of Science ®Google Scholar
• van der Velden V. H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., van Dongen J. J. Detection of minimal residual disease in hematologic malignancies by real‐time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–34
   PubMed Web of Science ®Google Scholar
• Gabert J., Beillard E., van der Velden V. H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of ‘real‐time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer Program. Leukemia 2003; 17: 2318–57
   PubMed Web of Science ®Google Scholar
• Beillard E., Pallisgaard N., van der Velden V. H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real‐time’ quantitative reverse‐transcriptase polymerase chain reaction (RQ‐PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–86
   PubMed Web of Science ®Google Scholar
• van Dongen J. J., Seriu T., Panzer‐Grumayer E. R., Biondi A., Pongers‐Willemse M. J., Corral L., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–38
   PubMed Web of Science ®Google Scholar
• Cave H., van der Werff ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998; 339: 591–98
   PubMed Web of Science ®Google Scholar
• Jacquy C., Delepaut B., Van Daele S., Vaerman J. L., Zenebergh A., Brichard B., et al. A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140–6
   PubMed Web of Science ®Google Scholar
• Gruhn B., Hongeng S., Yi H., Hancock M. L., Rubnitz J. E., Neale G. A., et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12: 675–81
   PubMed Web of Science ®Google Scholar
• Foroni L., Harrison C. J., Hoffbrand A. V., Potter M. N. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis. Br J Haematol 1999; 105: 7–24
   PubMed Web of Science ®Google Scholar
• Coustan‐Smith E., Behm F. G., Sanchez J., Boyett J. M., Hancock M. L., Raimondi S. C., et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550–4
   PubMed Web of Science ®Google Scholar
• Coustan‐Smith E., Sancho J., Hancock M. L., Boyett J. M., Behm F. G., Raimondi S. C., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691–6
   PubMed Web of Science ®Google Scholar
• Coustan‐Smith E., Sancho J., Hancock M. L., Razzouk B. I., Ribeiro R. C., Rivera G. K., et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100: 2399–402
   PubMed Web of Science ®Google Scholar
• Dworzak M. N., Froschl G., Printz D., Mann G., Potschger U., Muhlegger N., et al. Austrian Berlin‐Frankfurt‐Munster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952–8
   PubMed Web of Science ®Google Scholar
• Pott C., Schrader C., Gesk S., Harder L., Tiemann M., Raff T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard‐risk acute lymphoblastic leukemia. Blood 2006; 107: 1116–23
   Google Scholar
• Minucci S., Cioce M., Maccarana M., Pelicci P. G. The APL‐associated fusion proteins. Haematologica 1999; 84(Suppl EHA‐4)70–1
   Google Scholar
• Mistry A. R., Pedersen E. W., Solomon E., Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 2003; 17: 71–97
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Diverio D., Pandolfi P. P., Biondi A., Rossi V., Avvisati G., et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437–8
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Diverio D., Falini B., Biondi A., Nervi C., Pelicci P. G. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12–22
   PubMed Web of Science ®Google Scholar
• Testi A. M., Biondi A., Lo Coco F., Moleti M. L., Giona F., Vignetti M., et al. GIMEMA‐AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447–53
   PubMed Web of Science ®Google Scholar
• Lo Coco F., Diverio D., Avvisati G., Petti M. C., Meloni G., Pogliani E. M., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–9
   PubMed Web of Science ®Google Scholar
• Burnett A. K., Grimwade D., Solomon E., Wheatley K., Goldstone A. H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all‐trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–43
   PubMed Web of Science ®Google Scholar
• Cassinat B., Zassadowski F., Balitrand N., Barbey C., Rain J. D., Fenaux P., et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real‐time RT‐PCR. Leukemia 2000; 14: 324–8
   Google Scholar
• Gallagher R. E., Yeap B. Y., Bi W., Livak K. J., Beaubier N., Rao S., et al. Quantitative real‐time RT‐PCR analysis of PML‐RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521–8
   PubMed Web of Science ®Google Scholar
• Deininger M. W., Goldman J. M., Melo J. V. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–56
   PubMed Web of Science ®Google Scholar
• Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr‐Abl positive cells. Nat Med 1996; 2: 561–6
   PubMed Web of Science ®Google Scholar
• Druker B. J., Sawyers C. L., Kantarjian H., Resta D. J., Reese S. F., Ford J. M., et al. Activity of a specific inhibitor of the BCR‐ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–42
   PubMed Web of Science ®Google Scholar
• Marin D., Marktel S., Szydlo R., Klein J. P., Bua M., Foot N., et al. Survival of patients with chronic‐phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet 2003; 362: 617–9
   Google Scholar
• O'Brien S. G., Guilhot F., Larson R. A., Gathmann I., Baccarani M., Cervantes F., et al. IRIS Investigators. Imatinib compared with interferon and low‐dose cytarabine for newly diagnosed chronic‐phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Hughes T. P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M. L., et al. ; International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–32
   PubMed Web of Science ®Google Scholar
• Graham S. M., Jorgensen H. G., Allan E., Pearson C., Alcorn M. J., Richmond L., et al. Primitive, quiescent, Philadelphia‐positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–25
   PubMed Web of Science ®Google Scholar
• Gorre M. E., Sawyers C. L. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9: 303–7
   PubMedGoogle Scholar
• Talpaz M., Shah N. P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib‐resistant Philadelphia chromosome‐positive leukemias. N Engl J Med 2006; 354: 2531–41
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib‐resistant CML and Philadelphia chromosome‐positive ALL. N Engl J Med 2006; 354: 2542–51
   PubMed Web of Science ®Google Scholar
• Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR‐ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37
   PubMed Web of Science ®Google Scholar